Pharmafile Logo

Research conducted for Johnson and Johnson published in scientific journal

April 17, 2024 |  

Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.

- PMLiVE

The study, led by Johnson and Johnson, explored using real world evidence collected by patient records from physicians to examine the impact of genetic mutations on response to therapy in urothelial carcinoma.

The paper is titled ‘Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma’ and was published in Clinical Genitourinary Cancer. It explores the impact of FGFR mutations on response to different first-line anti-tumor regimens treating locally advanced or metastatic urothelial carcinoma. A total of 104 physicians treating first-line locally advanced or metastatic patients with systemic therapy contributed a total of 414 eligible patient records for the real-world evidence study. Findings showed that although FGFR mutations did not impact the overall progression free survival relative to wild type FGFR patients, the subset of gene mutation patients who received first-line immune checkpoint inhibitors without chemotherapy had significantly higher rates of progression relative to wild type patients receiving immune checkpoint inhibitors without chemotherapy.

For this project, Research Partnership was responsible for the survey design, enrolling respondents via fieldwork partners, performing analysis, both internally and with an external statistical analysis partner, as well as reading and approving drafts of the manuscript. We were privileged to assist our partners as they work to better understand responses to anti-tumor therapy in this malignancy and help oncologists refine the optimal treatment for patients.

Find out more and read the full publication. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

News: Living with Ulcerative Colitis and Crohn’s Disease

Living with Ulcerative Colitis (UC) and Crohn’s Disease (CD) are new patient syndicated reports which offer valuable insights into patient attitudes and behaviour towards their condition, treatments and unmet needs. These reports...

Interactive infographic

Living With: The journey from the patient’s perspective

Article: Spotlight on Mexico

Healthcare under AMLO – One year on

News: Mandira Kar joins London Headquarters as Qualitative Research Director

Research Partnership are delighted to announce that Mandira Kar has joined as a Qualitative Research Director. Mandira is an expert in ethnography with over 15 years’ experience in market research,...

Announcing a change of leadership at the US Philadelphia office

Research Partnership’s Philadelphia office is announcing a change of leadership from the start of 2020. President Harriet Kozak will be stepping down in order to take retirement at the end...

Article: Market access in Brazil

All eyes on Spinraza

China: How to strategise and win in the world’s fastest changing healthcare market

In this paper, experts Marc Yates, Pei Li Teh and Brett Gardiner discuss the China healthcare reforms which affect pharma and propose how to build the market understanding required to launch...

Article: Engaging patient advocacy groups

The key to conducting effective rare disease research

Webcast: Harnessing the power of social: How to generate fresh insights for your business using social media listening

Download our third Innovation in #MRX webcast, hosted in partnership with Convosphere, where we discuss how to use social media listening to answer key business questions.Watch here: https://bit.ly/2nM0xvj